A multimodal dataset for precision oncology in head and neck cancer
- PMID: 40759646
- PMCID: PMC12322140
- DOI: 10.1038/s41467-025-62386-6
A multimodal dataset for precision oncology in head and neck cancer
Abstract
Head and neck cancer is a common disease and is associated with a poor prognosis. A promising approach to improving patient outcomes is personalized treatment, which uses information from a variety of modalities. However, only little progress has been made due to the lack of large public datasets. We present a multimodal dataset, HANCOCK, that comprises monocentric, real-world data of 763 head and neck cancer patients. Our dataset contains demographical, pathological, and blood data as well as surgery reports and histologic images, that can be explored in a low-dimensional representation. We can show that combining these modalities using machine learning is superior to a single modality and the integration of imaging data using foundation models helps in endpoint prediction. We believe that HANCOCK will not only open new insights into head and neck cancer pathology but also serve as a major source for researching multimodal machine-learning methodologies in precision oncology.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: A.H. declares general disclosures (Honoraria for lectures or consulting/advisory boards for AbbVie, AstraZeneca, Biocartis, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Gilead, Illumina, Ipsen, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, QUIP GmbH, and other research support from AstraZeneca, Biocartis, Cepheid, Gilead, Illumina, Janssen, Novartis, Owkin, Qiagen, QUIP GmbH). ME declares general disclosures (Personal fees, travel costs, and speaker’s honoraria from Zytomed Systems, Merck, Eisai, MSD, AstraZeneca, Janssen-Cilag, Cepheid, Roche, Astellas, Diaceutics, Owkin, BMS, BicycleTX, QuiP GmbH; research funding from AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead, Owkin, QUIP GmbH, BicycleTX; advisory roles for Ferring, Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth, Owkin, BMS, BicycleTX, Merck; member of the clinical advisory board of BicycleTX; stock ownership: BicycleTX.). All other authors declare no competing interests.
Figures
References
-
- Sung, H. et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin.71, 209–249 (2021). - PubMed
-
- Budach, V. & Tinhofer, I. Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic review. Lancet Oncol.20, 313–326 (2019). - PubMed
-
- Gatta, G. et al. Prognoses and improvement for head and neck cancers diagnosed in europe in early 2000s: The eurocare-5 population-based study. Eur. J. Cancer51, 2130–2143 (2015). - PubMed
-
- Chow, L. Q. Head and neck cancer. N. Engl. J. Med.382, 60–72 (2020). - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
